Clinuvel Pharmaceuticals Limited Share Price Deutsche Boerse AG
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.950 EUR | 0.00% |
|
-0.83% | -15.00% |
| 16/06 | Clinuvel Pharmaceuticals Advances US Listing Plan With SEC Filing for Nasdaq ADS Upgrade | MT |
| 28/04 | Clinuvel Pharmaceuticals plans level II ADR upgrade and Nasdaq listing as CUVL | RE |
| Market Cap | 50Cr 35Cr 30Cr 28Cr 26Cr 49Cr 3.28TCr 337.89Cr 130.75Cr 1.62TCr 130.61Cr 127.76Cr 5.62TCr | P/E 2026 * |
14x | P/E 2027 * | 13.2x |
|---|---|---|---|---|---|
| Enterprise Value | 25Cr 17Cr 15Cr 14Cr 13Cr 24Cr 1.63TCr 167.73Cr 65Cr 805.01Cr 65Cr 63Cr 2.79TCr | EV / Sales 2026 * |
2.51x | EV / Sales 2027 * | 2.07x |
| Free-Float |
83.79% | Yield 2026 * |
0.61% | Yield 2027 * | 0.8% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 week | -0.83% | ||
| Current month | +12.26% | ||
| 1 month | +12.26% | ||
| 3 months | +3.30% | ||
| 6 months | -17.93% | ||
| Current year | -15.00% |
| 1 week | 5.7 |  | 6 |
| 1 month | 5.1 | | 6 |
| Current year | 5.1 | | 7.39 |
| 1 year | 5.1 | | 7.68 |
| 3 years | 4.8 | | 12.68 |
| 5 years | 4.8 | | 27 |
| 10 years | 2.68 | | 27 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -0.83% | - | - | 35Cr | |
| +2.06% | +3.76% | +21.48% | -19.31% | 6.44TCr | |
| +0.74% | +3.52% | +53.14% | +219.37% | 5.61TCr | |
| -3.10% | +34.30% | +34.30% | +34.30% | 4.05TCr | |
| -2.36% | -1.25% | -52.13% | -58.98% | 3.8TCr | |
| +6.97% | +9.89% | +70.21% | -23.28% | 3.19TCr | |
| +12.59% | +5.18% | +144.26% | -44.13% | 2.67TCr | |
| +5.78% | +15.81% | +60.64% | +80.73% | 2.27TCr | |
| -1.25% | -1.31% | -4.39% | +142.42% | 1.67TCr | |
| -0.81% | +5.91% | +67.70% | +124.13% | 1.66TCr | |
| Average | +2.06% | +4.32% | +43.91% | +50.58% | 3.48TCr | |
| Weighted average by Cap. | +1.96% | +4.11% | +39.20% | +46.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.95Cr 6.87Cr 6.02Cr 5.55Cr 5.2Cr 9.74Cr 647.82Cr 67Cr 26Cr 320.17Cr 26Cr 25Cr 1.11TCr | 11Cr 7.27Cr 6.38Cr 5.88Cr 5.5Cr 10Cr 686.21Cr 71Cr 27Cr 339.14Cr 27Cr 27Cr 1.18TCr |
| Net income | 3.6Cr 2.48Cr 2.18Cr 2.01Cr 1.88Cr 3.52Cr 234.26Cr 24Cr 9.33Cr 115.78Cr 9.33Cr 9.12Cr 401.47Cr | 3.82Cr 2.64Cr 2.31Cr 2.13Cr 2Cr 3.74Cr 248.81Cr 26Cr 9.91Cr 122.97Cr 9.9Cr 9.69Cr 426.4Cr |
| Net Debt | -25Cr -18Cr -15Cr -14Cr -13Cr -25Cr -1.65TCr -170.16Cr -66Cr -816.67Cr -66Cr -64Cr -2.83TCr | -29Cr -20Cr -17Cr -16Cr -15Cr -28Cr -1.86TCr -191.85Cr -74Cr -920.76Cr -74Cr -73Cr -3.19TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/26/26 | €5.950 | 0.00% | 0 |
| 25/26/25 | €5.950 | +4.39% | 0 |
| 24/26/24 | €5.700 | -5.00% | 0 |
| 23/26/23 | €6.000 | 0.00% | 500 |
| 22/26/22 | €6.000 | 0.00% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
Select your edition
All financial news and data tailored to specific country editions
